Oxaliplatin

Category:

Description

Oxaliplatin

Description

1.1. Name (ICH 3.2.S.1.1)

International non-proprietary name: Oxaliplatin (Brand Name: Eloxatin)

Compendial name: Oxaliplatin

Chemical name: [SP-4-2-(1R-trans)]-(1, 2-Cyclohexanediamine-N,N′)[ethanedioato(2-)-O,O’] platinum.

Arasto’s code: OXA

CAS Registry Number: [61825-94-3].

Official Pharmacopoeia Monograph: USP 44

 

Drug Substance General Information (ICH 3.2.S.1)

1.2. Structure (ICH 3.2.S.1.2)

Empirical Formula: C8H14N2O4Pt

Molecular Weight: 397.29 g/mol

1. Drug Substance General Information (ICH 3.2.S.1)
1.3. General Properties (ICH 3.2.S.1.3)
Oxaliplatin is a white to off-white powder and it is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone at 25°C. Oxaliplatin melting point is over 245°C and about 260°C. Decomposition temperature is not established. 5 mg per ml of Oxaliplatin in distilled water is clear and has Specific rotation of between +74.58 and +78.08 at 20°C. A 5mg/ml solution of Oxaliplatin in water has a pH of 4.0-7.0 at 25°C. (http://www.sagentpharma.com/wp-content/uploads/2014/12/Oxaliplatin_SDS.pdf). Oxaliplatin (1-OHP; L-OHP) is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. Oxaliplatin is classified as an “alkylating agent” and it is used to treat colon or rectal cancer that has spread (metastasized). It is often given in combination with other anticancer drugs (fluorouracil and leucovorin).
The determination of purity and assay of APIs require comparison of the product with their respective Reference Standards (RS) and Related Compounds (RC or known impurities). Accordingly, ICH regulations on the purity and assay of reference standard and related compounds are clearly defined and must be followed by drug substance and drug product manufacturers.
According to ICH Q7, 11.1 there are 3 types of standards. This is summarized in the following chart and discussed in detail below.

The impurities provided in the following table represent Secondary Reference Standards (SRS) that are prepared in-house by synthesis or by isolation. Each SRS has undergone extensive characterization (IR, UV, 1HNMR, 13CNMR. Mass Spec) and determination of its purity and assay (HPLC). For specification of the SRS of those products that have a monograph, the SRS is compared with a pharmacopoeia Primary Reference Standard (UV, HPLC retention time). For specification of those products that do not have a monograph (known as House Primary Standard), we compare their UV ε or ג /max , IR major absorptions, 1HNMR d (ppm) , 13 CNMR d (ppm) or HPLC retention time with values reported in the chemical literature for these compounds.

Oxaliplatin Related Compounds

5. Primary and Secondary Reference Standard (ICH 3.2.S.5)

5.1. Active Pharmaceutical Ingredient

Primary Reference Standard for Oxaliplatin is available from United States Pharmacopoeia. We will use a Secondary Reference Standard (previously referred to as Working Standard) for direct control of all batches of Oxaliplatin.
As per ICH (Q7, 11.1) and ICH (Q6, 2.11, 3.2, 3.3) House Primary Standards, which include the API and its Related Compounds, must be examined for their proof of structure (characterization), assay and purity and specification (identification by comparison). Furthermore, ICH Guideline on the Preparation of Common Technical Document (Q4M) requires that the data obtained from characterization, assay and purity and specification must be included in section 3.2.S.3.2 for Related Compounds (already discussed in that section) and section 3.2.S.5 of the DMF for the API. To this end, the House Primary Standard of the API Oxaliplatin has undergone extensive characterization (UV, IR, 1 H NMR, 13C NMR, Mass Spec) to assure its structure, assay and purity (HPLC and/or titration) and specification.
The Secondary Reference Standard for Oxaliplatin was produced from a released batch of Oxaliplatin by subjecting it to an additional crystallization from the final solvent system used in the production of the API to avoid the possibility of other polymorph formation.

Related products

Oxaliplatin

Category:

Description

Oxaliplatin

Description

1.1. Name (ICH 3.2.S.1.1)

International non-proprietary name: Oxaliplatin (Brand Name: Eloxatin)

Compendial name: Oxaliplatin

Chemical name: [SP-4-2-(1R-trans)]-(1, 2-Cyclohexanediamine-N,N′)[ethanedioato(2-)-O,O’] platinum.

Arasto’s code: OXA

CAS Registry Number: [61825-94-3].

Official Pharmacopoeia Monograph: USP 44

 

Drug Substance General Information (ICH 3.2.S.1)

1.2. Structure (ICH 3.2.S.1.2)

Empirical Formula: C8H14N2O4Pt

Molecular Weight: 397.29 g/mol

1. Drug Substance General Information (ICH 3.2.S.1)
1.3. General Properties (ICH 3.2.S.1.3)
Oxaliplatin is a white to off-white powder and it is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone at 25°C. Oxaliplatin melting point is over 245°C and about 260°C. Decomposition temperature is not established. 5 mg per ml of Oxaliplatin in distilled water is clear and has Specific rotation of between +74.58 and +78.08 at 20°C. A 5mg/ml solution of Oxaliplatin in water has a pH of 4.0-7.0 at 25°C. (http://www.sagentpharma.com/wp-content/uploads/2014/12/Oxaliplatin_SDS.pdf). Oxaliplatin (1-OHP; L-OHP) is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. Oxaliplatin is classified as an “alkylating agent” and it is used to treat colon or rectal cancer that has spread (metastasized). It is often given in combination with other anticancer drugs (fluorouracil and leucovorin).
The determination of purity and assay of APIs require comparison of the product with their respective Reference Standards (RS) and Related Compounds (RC or known impurities). Accordingly, ICH regulations on the purity and assay of reference standard and related compounds are clearly defined and must be followed by drug substance and drug product manufacturers.
According to ICH Q7, 11.1 there are 3 types of standards. This is summarized in the following chart and discussed in detail below.

The impurities provided in the following table represent Secondary Reference Standards (SRS) that are prepared in-house by synthesis or by isolation. Each SRS has undergone extensive characterization (IR, UV, 1HNMR, 13CNMR. Mass Spec) and determination of its purity and assay (HPLC). For specification of the SRS of those products that have a monograph, the SRS is compared with a pharmacopoeia Primary Reference Standard (UV, HPLC retention time). For specification of those products that do not have a monograph (known as House Primary Standard), we compare their UV ε or ג /max , IR major absorptions, 1HNMR d (ppm) , 13 CNMR d (ppm) or HPLC retention time with values reported in the chemical literature for these compounds.

Oxaliplatin Related Compounds

5. Primary and Secondary Reference Standard (ICH 3.2.S.5)

5.1. Active Pharmaceutical Ingredient

Primary Reference Standard for Oxaliplatin is available from United States Pharmacopoeia. We will use a Secondary Reference Standard (previously referred to as Working Standard) for direct control of all batches of Oxaliplatin.
As per ICH (Q7, 11.1) and ICH (Q6, 2.11, 3.2, 3.3) House Primary Standards, which include the API and its Related Compounds, must be examined for their proof of structure (characterization), assay and purity and specification (identification by comparison). Furthermore, ICH Guideline on the Preparation of Common Technical Document (Q4M) requires that the data obtained from characterization, assay and purity and specification must be included in section 3.2.S.3.2 for Related Compounds (already discussed in that section) and section 3.2.S.5 of the DMF for the API. To this end, the House Primary Standard of the API Oxaliplatin has undergone extensive characterization (UV, IR, 1 H NMR, 13C NMR, Mass Spec) to assure its structure, assay and purity (HPLC and/or titration) and specification.
The Secondary Reference Standard for Oxaliplatin was produced from a released batch of Oxaliplatin by subjecting it to an additional crystallization from the final solvent system used in the production of the API to avoid the possibility of other polymorph formation.

Related products